Escitalopram (oxalate)

Escitalopram ((S) -Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R (-) -enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET) . Escitalopram oxalate is an antidepressant for the research of major depression[1][2].

Product Specifications

CAS Number

[219861-08-2]

Product Name Alternative

(S) -Citalopram (oxalate) ; (S) - (+) -Citalopram (oxalate)

UNSPSC

12352005

Hazard Statement

H410

Target

Serotonin Transporter

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Escitalopram-oxalate.html

Purity

99.88

Solubility

DMSO : 116.67 mg/mL (ultrasonic) |H2O : ≥ 14.29 mg/mL

Smiles

FC1=CC=C([C@@]2(CCCN(C)C)C(C=CC(C#N)=C3)=C3CO2)C=C1.O=C(O)C(O)=O

Molecular Formula

C22H23FN2O5

Molecular Weight

414.43

Precautions

H410

References & Citations

[1]Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1- (3- (dimethylamino) propyl) -1- (4-fluorophenyl) -1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53 (16) : p. 6112-21.|[2]Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10 (1) : p. 121-8.|[3]Wu C , et al. Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity. Neurobiol Aging. 2018;67:137-147.|[4]Cirrito JR, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95 (19) :e2666-e2674.